Small‐molecule therapeutics blocking S100A8/A9 activity has been demonstrated to be safe in humans.[37, 38, 39] Tasquinimod has been designated an orphan drug by the U.S. Food and Drug Administration for the treatment of multiple myeloma in 2017. Here, IGKV1D-22 is linked to plasma cell myeloma.